Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 15, 2008 - Issue 2
110
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Multi-elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy patients

, , , , , , & show all
Pages 108-116 | Published online: 06 Jul 2009
 

Abstract

There is accumulating evidence of the involvement of biological metal imbalance in the progression of amyloid diseases such as Alzheimer's, Parkinson's and prion diseases. However, the mineral status in patients affected with familial amyloidotic polyneuropathy (FAP) has not been investigated. It is the aim of this study to determine the metal concentrations in the serum and in the transthyretin (TTR) amyloid fibrils of FAP amyloidogenic TTR (ATTR) V30M patients. Multi-elemental analysis of 17 metals by high-resolution inductively coupled plasma mass spectrometry (ICP-MS) revealed a significant decrease of the metals Fe, Cu, Zn, Cs and Ba in the serum of FAP patients (mean age 38.5 ± 8.3 years; duration of disease 4 ± 2.6 years) in comparison with that of healthy individuals (mean age 36.2 ± 9.2 years). On the other hand, these metals, except Cs, were found at high levels in the amyloid fibrils of FAP patients (mean age 55.8 ± 9.2; duration of disease 6.5 ± 1.3 years) compared with other metals. These findings firstly suggest that the mineral status could be a candidate factor, which participates in the wide spectrum of clinical pictures of FAP patients.

Abbreviations
FAP=

familial amyloid polyneuropathy

ICP-MS=

inductively coupled plasma mass spectroscopy

TTR=

transthyretin

AD=

Alzheimer's disease

PD=

Parkinson's disease

IS=

internal standard

LOD=

limit of detection

LOQ=

limit of quantification

Abbreviations
FAP=

familial amyloid polyneuropathy

ICP-MS=

inductively coupled plasma mass spectroscopy

TTR=

transthyretin

AD=

Alzheimer's disease

PD=

Parkinson's disease

IS=

internal standard

LOD=

limit of detection

LOQ=

limit of quantification

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.